D-0049-2015 Class III Terminated
FDA drug recall D-0049-2015 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Oct 21, 2014 and is designated Class III. Reason for recall: Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for… The recall status is terminated (terminated Apr 3, 2017). Affected quantity: 1,966 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 5, 2014
- Initiation Date
- Oct 21, 2014
- Termination Date
- Apr 3, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,966 bottles
Product description
Carbamazepine Tablets USP, 200 mg, 1000 Tablets per Bottle, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 26110 Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4005-3.
Reason for recall
Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for the Carbamazepine API final intermediate was pending approval.
Distribution pattern
IL, OH, LA
Code information
Lot 137393, exp. 10/2016
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0049-2015
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026